Mesna
Langerhan's Cell Histiocytosis
Masonic Cancer Center, University of MinnesotaSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the Langerhan's Cell Histiocytosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat National Cancer Institute (NCI) | Phase 2 | B |
Clofarabine M.D. Anderson Cancer Center | Phase 2 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
Fludarabine M.D. Anderson Cancer Center | Phase 2 | B |
Evomela M.D. Anderson Cancer Center | Phase 2 | B |
View all 28 →
Same molecule, other indications
Mesna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →